Amryt Pharma Plc
AMYT:LN
Overview
Company Profile
Amryt is a biopharmaceutical company dedicated to developing and delivering innovative new treatments to help improve the lives of patients with rare and debilitating diseases. Amryt comprises a profitable and growing commercial business with a significant development pipeline.
A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to our stakeholders and most importantly our patients, we create a clear path for our transformative medicines to reach those that need them.
Classification
Sector Healthcare
Industry Pharmaceuticals
Subindustry Pharmaceutical Manufacturers - Specialty & Generic
Financials
Corporate
Board of Directors
Dr. Joe Wiley
Chief Executive Officer (CEO)
Dr. Wiley founded Amryt and has over 20 years of experience in the pharmaceutical, medical and venture capital industries. Dr. Wiley opened and led the European office of Sofinnova Ventures Inc. He was previously a medical director at Astellas Pharma Limited where he liaised with the marketing team and was involved in the launch of a number of specialty pharmaceutical products. Prior to joining Astellas Pharma Limited, he held investment roles at Spirit Capital SA, Inventages Venture Capital Investment Inc. and Aberdeen Asset Managers Private Equity Limited. Dr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. He has a Masters of Business Administration from INSEAD and is also a Member of the Royal College of Physicians in Ireland. Dr.Wiley will continue as Chief Executive Officer of the Enlarged Group for no less than two years after Closing, unless he resigns or is removed from the position by a vote of a majority of the Board
Ray Stafford
Non-executive Chairman
Mr. Stafford has worked in the pharmaceutical industry for thirty years. He was Chairman, Chief Executive Officer and majority shareholder of the Tosara Group who owned, manufactured and marketed the successful international brand Sudocrem. Tosara was integrated into the US based NYSE listed company Forest Laboratories, Inc. in 1988. Mr. Stafford held numerous senior positions within that corporation including Chief Executive Officer of Forest UK and Ireland as well as Chief Executive Officer of Forest Laboratories Europe since 1999. Mr. Stafford retired in 2014 following the sale of Forest Laboratories, Inc. to Actavis Plc (now Allergan Plc) in a US $28 billion transaction where Mr. Stafford was Executive Vice President of Global Marketing. Separately, Mr. Stafford was founder of what is today one of Ireland’s leading multi-channel sales, marketing and distribution service providers approved by the Irish Medicines Board (now The Health Products Regulatory Authority) to service the wholesale and retail trade.
Stephen Wills
Non-executive Director
Mr.Wills serves as the Chief Financial Officer, since 1997, and Chief Operating Officer, since 2011, of Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Mr.Wills also serves on the boards of: Caliper Corporation, since 2016; MediWound Ltd., since 2017; and Gamida Cell Ltd., since 2019. Mr.Wills served as Executive Chairman and Interim Principal Executive Officer of Derma Sciences, Inc., a public company providing advanced wound care products, from December 2015 until February 2017 when Derma Sciences, Inc. was acquired by Integra LifeSciences Holding Corporation. Mr. Wills also served as the lead director of Derma Sciences, Inc. until December 2015 and as Chief Financial Officer from 1997 to 2000. Mr. Wills is 531 Chairman of the board of trustees of The Hun School of Princeton, New Jersey and from 1991 to 2000 he was the President and Chief Operating Officer of Golomb,Wills & Company, P.C., a public accounting firm. Mr. Wills is a certified public accountant and earned his Bachelor of Science in accounting from West Chester University and a Master of Science in taxation from Temple University.
Dr. Patrick Vink
Non-executive Director
Dr.Vink has significant experience as a senior executive having worked in the pharmaceutical industry for more than 30 years. Dr. Vink serves as Chairman at Acacia Pharma Group plc and Targovax ASA, both publicly listed biopharma companies based in the UK and Norway. Dr. Vink also serves as Chairman of venture capital backed NMD Pharma ApS, a neurology biopharma company in Denmark and F2G Ltd, a rare fungal disease UK- and Austria-based company. In addition, Dr. Vink is a board member at Santhera AG and Spero Therapeutics Inc and since 2019 began working with Athyrium as a Senior Advisor. While serving at these companies, Dr. Vink has been involved in initial public listings, geographic expansions and contributed to the achievement of meaningful development and commercial milestones. Earlier in his career he held several leadership positions across the industry, including Head of Global Biopharmaceuticals for the Sandoz division of the Novartis Group, Vice President International Business for Biogen Inc., and Head of Worldwide Marketing, Cardiovascular and Thrombosis at Sanofi-Synthelabo Ltd. Dr.Vink also served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations between 2013 and 2015. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his Masters of Business Administration in 1992 at the University of Rochester.
Donald Stern
Non-executive Director
Mr. Stern was previously a director of Novelion until September 2019, and previously a member of Aegerion’s board of directors from September 2015 through to October 2016.Mr. Stern is Managing Director of Corporate Monitoring & Consulting Services at Affiliated Monitors Inc., a consulting firm providing independent integrity monitoring services and compliance services across a wide range of regulated industries and professions. He has had a diverse and distinguished legal career, evenly split between private practice and public service. He has been a partner at three major law firms including Cooley LLP, Bingham McCutchen LLP, and Hale & Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP). Mr. Stern has served as the United States Attorney for the District of Massachusetts, the Chief Legal Counsel to Governor Michael S. Dukakis and the Chief of the Government Bureau in the Massachusetts Attorney General’s office. Mr. Stern holds a Masters in Laws from University of Pennsylvania Law School, a Juris Doctor degree from Georgetown University Law Center and a Bachelor of Arts from Hobart College.
Dr. Alain Munoz
Non-executive Director
Dr. Munoz, M.D., Ph.D. is an entrepreneur and independent management consultant in the pharmaceutical and biotechnology industry, and has over 30 years of experience in the industry at the executive level. Dr. Munoz worked with the Fournier Group, as Research and Development director and then Senior Vice President of the Pharmaceutical Division. He joined the Fournier Group from Sanofi Group, where he started as director in the cardiovascular and anti-thrombotic products department and then asVice President international development. Dr.Munoz is qualified in cardiology and anaesthesiology from the University Hospital of Montpellier, France where he was head of the clinical cardiology department. He has been a member of the Scientific Committee of the French drug agency. He is advisor to Kurma Partners and serves on the scientific advisory board of Valneva SA. He is an independent board member of Hybrigenics S.A., Auris Medical Holding AG and Zealand Pharma A/S.
George Hampton Jr
Non-executive Director
Mr. Hampton joined Currax Pharmaceuticals in April of 2019 as Chief Executive Officer and serves on its board of directors. Prior to joining Currax, Mr. Hampton served as executive vice president, primary care business unit for Horizon Pharmaceuticals (HZNP), a public biopharmaceutical company. In this role he was tasked with leading the forward-looking strategy, as well as establishing operational goals for the business. Previously, Mr. Hampton served as executive vice president, global orphan business unit and international operations for Horizon Pharmaceuticals. He has more than 25 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rare disease (ACTIMMUNE, RAVICTI, PROCYSBI), autoimmune (HUMIRA), primary care, orthopedic (CELEBREX), diabetes (BYETTA), anti-infectives and cardiovascular spaces. This includes roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott, (now AbbVie), Amylin and Horizon Pharmaceuticals. Hampton earned his Bachelor of Science from Miami University in Oxford, Ohio. He serves on the board of IMAC (NASDAQ: IMAC) regeneration centers, pubic regenerative medicine centers.
Senior Management
Dr. Joe Wiley
Chief Executive Officer (CEO)
Dr. Wiley founded Amryt and has over 20 years of experience in the pharmaceutical, medical and venture capital industries. Dr. Wiley opened and led the European office of Sofinnova Ventures Inc. He was previously a medical director at Astellas Pharma Limited where he liaised with the marketing team and was involved in the launch of a number of specialty pharmaceutical products. Prior to joining Astellas Pharma Limited, he held investment roles at Spirit Capital SA, Inventages Venture Capital Investment Inc. and Aberdeen Asset Managers Private Equity Limited. Dr. Wiley trained in general medicine at Trinity College Dublin, specialising in neurology. He has a Masters of Business Administration from INSEAD and is also a Member of the Royal College of Physicians in Ireland. Dr.Wiley will continue as Chief Executive Officer of the Enlarged Group for no less than two years after Closing, unless he resigns or is removed from the position by a vote of a majority of the Board
Rory Nealon
Chief Financial Officer and Chief Operating Officer (CFO & COO)
Rory Nealon co-founded Amryt Pharma in August 2015. Prior to that, he was the Chief Financial Officer (from 2003), Chief Operating Officer (from November 2007) and Board Member of Trinity Biotech plc, a diagnostic company listed on Nasdaq. He has also been a Board Member and Chief Financial Officer of Conduit plc, an Irish directory services provider with operations in Ireland, the UK, Austria and Switzerland, as well as an Associate Director at AIB Capital Markets, a subsidiary of AIB Group plc, the Irish banking group. He holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, a member of the Institute of Taxation in Ireland and a member of the Institute of Corporate Treasurers in the UK.
Dr. Mark Sumeray
Chief Medical Officer (CMO)
Dr Mark Sumeray joined Amryt Pharma in September 2016. He has almost 20 years’ experience across the pharmaceutical, medical devices and biotech industries, both in the US and UK. Most recently, he spent five years as Chief Medical Officer at Aegerion Pharmaceuticals, a US-based orphan disease biotech company. While there, he had clinical development, medical affairs and pharmacovigilance responsibility for the global approval and launch of a new treatment, Lojuxta®▼(lomitapide), for the serious and rare genetic disease, Homozygous Familial Hypercholesterolemia. He led the clinical and scientific interactions with global health authorities, including the US Food and Drug Administration. Prior to Aegerion, he was at Bristol-Myers Squibb, where he led a large US medical affairs team within the cardiovascular and metabolics area. He also previously worked at Ethicon, a Johnson & Johnson medical device company, where he was responsible for the clinical group. He spent nine years in clinical practice in the NHS, specialising in cardiovascular surgery and physiology, having qualified as a medical doctor at the University of London.
David Allmond
Chief Commercial Officer (CCO)
David Allmond joined Amryt Pharma as Chief Commercial Officer in March 2017. Prior to joining Amryt, he was President Europe, Middle East and Africa (EMEA) at Aegerion Pharmaceuticals, where he was responsible for the commercialisation of Lojuxta (lomitapide), a treatment for Homozygous Familial Hypercholesterolemia (HoFH) recently in-licensed by Amryt Pharma. Mr. Allmond was previously Corporate Vice President of Global Marketing at Celgene, where he played a pivotal role in defining strategy for in-line brands, lifecycle/pipeline prioritisation and commercial direction for business development. He was also responsible for EMEA marketing and market access.
Dr. Helen Phillips
Head of Medical Affairs
Dr Helen Phillips joined Amryt Pharma in December 2016. Prior to joining, she was Medical Director EMEA at Aegerion Pharmaceuticals, where she was responsible for the medical activities supporting Lojuxta (lomitapide), a treatment for Homozygous Familial Hypercholesterolaemia (HoFH). Dr. Phillips has over 20 years’ experience in Medical Affairs, working in UK, European and Global roles for AstraZeneca, GSK and Hospira, as well as biotech start-up companies, Aspreva and Vanda. She has a degree in Medicine from Bristol University Medical School and spent six years in the NHS in General Practice.
Kieran Rooney
VP, Strategic Alliances and Licensing
Kieran Rooney joined Amryt Pharma as VP, Strategic Alliances and Licensing, in August 2017. Prior to joining Amryt, he was Managing Director of Halo BioConsulting, a global healthcare advisory services firm he founded in 2007, which focused on business alliances and management consulting. Between 2007 and 2017, he worked with over 30 pharmaceutical, biotechnology and professional service companies, including, most recently, Amakem Therapeutics and PwC. Prior to that, Dr. Rooney worked as a consultant to the UK Government and held business development roles at Smith & Nephew, F2G Limited, Pharsight Corporation, and MDS Pharma Services, among others. He has a PhD in Neuropharmacology from the University of Wales, Cardiff.
Derval O’Carroll
Head of Regulatory Affairs
Derval has over 25 years’ experience in pharmaceutical industry regulatory affairs. Prior to joining Amryt, Derval was Senior Director of Regulatory Affairs for the NASDAQ‐listed rare diseases company Retrophin Inc., where she provided regulatory, strategic and operational input to product teams managing Retrophin’s development‐stage and commercial products. Before that, Derval worked for 11 years as a Managing Consultant at Real Regulatory Ltd, a consultancy specialising in European regulatory affairs, quality management systems and supply chain operations compliance
Stephen Joyce
VP, Global Marketing
Stephen joined Amryt Pharma as VP, Global Marketing in December 2018 with over 15 years’ experience in the pharmaceutical industry across multiple therapy areas. Most recently Stephen was General Manager, Switzerland at Astellas Pharmaceuticals AG, and prior to that he was Area Marketing & Market Access Director at Astellas Pharma EMEA. During this time, he played a pivotal role in multiple product launches, redefining portfolio and brand strategies, and multiple organisational change projects, whilst contributing to development of a new operating model for the EMEA region. He holds a BSc. in Marketing from Trinity College Dublin and has participated in the INSEAD Executive Leadership Programme.
Julie Eastwood
Head of Human Resources
Julie has over 25 years’ experience in HR. Her experience has been in multiple sectors in the UK and Republic of Ireland including Construction, Television, Technology and Waste Management. She joined Amryt in June 2019. Her former experience has included working as HR Director in Total mobile, TV3 and Oxigen. A Fellow of the Chartered Institute of Personnel and Development Julie holds a Master’s Degree in Administration and Law. She has significant experience in Employee Relations, Employee Engagement, Training and Development, Recruitment and Selection and in Acquisitions.
Gerry Gilligan
Head of Manufacturing Supply Chain
Gerry has over 25 years’ experience in the pharmaceutical sector. His experience has spanned Supply chain, API, Development, Solid Oral dosage, Semi Solid formulations, Bulk Manufacturing and Aseptic fill finish. He joined Amryt in February 2019. His most recent rolls have included Director of Manufacturing, Director of Operations and Site Lead at LEO Pharma. Gerry has a PhD in Chemistry, Black belt in Lean/ Quality Systems and most recently became a certified Business Coach. He has led organisations through significant operational transformation and been involved in acquisitions of companies and product portfolios.